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While early efforts in psychiatry were focused on uncovering the neurobiological basis of
psychiatric symptoms, they made little progress due to limited ability to observe the living
brain. Today, we know a great deal about the workings of the brain; yet, none of this
neurobiological awareness has translated into the practice of psychiatry. The categorical
system which dominates psychiatric diagnosis and thinking fails to match up to the real
world of genetics, sophisticated psychological testing, and neuroimaging. Nevertheless,
the American Psychiatric Association (APA) recently published a position paper stating
that neuroimaging provided no benefit to the diagnosis and treatment of psychiatric
disorders. Using the diagnosis of depression as a model, we illustrate how setting aside
the unrealistic expectation of a pathognomonic “fingerprint” for categorical diagnoses, we
can avoid missing the biological and, therefore, treatable contributors to psychopathology
which can and are visualized using functional neuroimaging. Infection, toxicity,
inflammation, gut-brain dysregulation, and traumatic brain injury can all induce
psychiatric manifestations which masquerade as depression and other psychiatric
disorders. We review these and provide illustrative clinical examples. We further
describe situations for which single photon emission computed tomography (SPECT)
and positron emission tomography (PET) functional neuroimaging already meet or exceed
the criteria set forth by the APA to define a neuroimaging biomarker, including the
differential diagnosis of Alzheimer's disease and other dementias, the differential
diagnosis of ADHD, and the evaluation of traumatic brain injury. The limitations, both
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real and perceived, of SPECT and PET functional neuroimaging in the field of psychiatry
are also elaborated. An important overarching concept for diagnostic imaging in all its
forms, including functional neuroimaging, is that imaging allows a clinician to eliminate
possibilities, narrow the differential diagnosis, and tailor the treatment plan. This
progression is central to any medical diagnostic process.
Keywords: SPECT, single photon emission computarized tomography, positron emision tomography (PET),
depression, inflammation, herpes, dementia, ADHD
INTRODUCTION
The medical application of X-rays was discovered by Wilhelm
Conrad Roentgen in 1895 (1, 2). Within a decade, x-rays were
being used in medicine, increasing dramatically during World
War I, and became standard of care within two decades. Gamma
radiation was discovered by Paul Villard in 1900 (1, 3). Almost
70 years later, David Kuhl and Roy Edwards harnessed gamma
radiation in the first gamma emission tomographs in 1964 (4).
Building upon the work of Hal Anger, who solved the problem of
geometrically analyzing gamma emissions from whole organs,
Ron Jaszczak and his colleagues developed the first whole body
SPECT camera in 1976 (4). The first medical study of functional
brain activity with SPECT neuroimaging was published in
1978 (5).
Unlike the X-ray, computed tomography (CT) and magnetic
resonance imaging (MRI), SPECT did not become a standard of
care in the fields of medicine devoted to the treatment of the
functioning and malfunctioning brain—Psychiatry and
Neurology, except for a brief period in the 1980s when brain
SPECT was used to evaluate the consequences of stroke and later
Alzheimer's disease. Over forty years after the development of
SPECT neuroimaging, these fields of medicine still ignore a
valuable tool for examining the functional status of the brain.
One must ponder the question—why?
BRAIN FUNCTION AND PSYCHIATRY IN
HISTORY
Ironically, Sigmund Freud, the father of psychoanalysis and its
attendant attribution of human behavior to ephemeral
intrapsychic agencies, such as the Id and Ego, actually began
his inquiry into human behavior by trying to understand the
functioning of the human brain (6). As detailed in his letter to
Wilhelm Fliess, Dr. Freud described impacts upon the nervous
system and explored the effects of sinus pathology upon the
workings of the brain—and ult imately the psyche.
Unfortunately, he did not have the tools to understand brain
function and its direct relationship to human behavior, and he
became frustrated.
The psychoanalytic movement that Freud sparked resulted in
the brain being ignored by psychiatry. This was to the detriment
of patients, including the notable Ukrainian-American
composer, George Gershwin, who died in 1937 of a slow-
growing brain tumor which was not caught earlier because his
psychiatrist was completely focused on trying to uncover the
psychoanalytic underpinnings of Gershwin's severe headaches.
His psychiatrist did not think or act like a doctor of medicine. He
ignored Gershwin's symptoms of sudden memory lapses,
olfactory hallucinations of the smell of burning rubber, bouts
of incoordination, and other clear signs of a neurological
disturbance. Gershwin is but one of thousands who died
needlessly because psychiatrists ignored the brain.
PSYCHIATRY IN THE MODERN ERA
But now we live in a more enlightened time. We recognize the
role of the amygdala, the thalamus, the hippocampus, the
dorso la tera l pre f ronta l cor tex , and the insu la in
neuropsychiatric function. We recognize that lesions to the
frontal cortex can disrupt judgement, motivation, and social
decorum. Psychiatric meetings and presentations are peppered
with pictures of the brain and often a functional MRI or two. Yet,
none of this neurobiological awareness has translated into the
practice of psychiatry. Psychiatrists seem to rely entirely on their
intuition to decide what is wrong with a patient. Some experts
state psychiatrists make a diagnosis in less than 15 minutes of
patient interview (7). Treatment decisions seem to be determined
by the psychiatrist's clinical experience, rather than scientific
evidence supporting clinical efficacy (8). If a patient appears
similar to a previous patient, then the newly diagnosed patient is
more likely to get the same medication that worked for the
previous patient (8, 9).
Mind you, there are diagnostic criteria for the diagnoses
established in Psychiatry. The Diagnostic and Statistical
Manual V (DSM-V) provides a set of symptoms and signs
which must be present to give a patient a certain diagnosis
(10). Most of these criteria are subjective, and the overlap
between diagnoses can be striking. For example, it is very
difficult to diagnose a patient with a personality disorder
without having sufficient diagnostic criteria to meet the DSM
diagnostic criteria for, yet, a second personality disorder.
Moreover, the diagnostic system of the DSMV was created by
committees and is artificial. Therefore, it is not surprising that
fully 60% of the DSMV diagnoses failed to stand up to validity
testing when subjected to field trials (11). Dr. Thomas Insel,
then-head of National Institutes of Mental Health, stated
(12, 13):
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The DSM-IV has 100% reliability and 0% validity …
We need to develop biomarkers, including brain
imaging, to develop the validity of these disorders …
Trial-and-error diagnosis will move to an era where
we understand the underlying biology of mental
disorders … We are going to have to use
neuroimaging to begin to identify the systems
pathology … to develop treatments that go after the
core pathology, understood by imaging.
In other words, the artificial groupings and separations of
symptoms do not match the real world experience, nor do they
match the neurobiological evidence. Nassir Ghaemi, MD, noted
expert on psychopharmacology recently wrote (14):
“Psychiatry … practice(s) non-scientifically; we use
hundreds of made-up labels for professional purposes,
without really getting at the reality of what is wrong
with the patient…
The DSM system which dominates Psychiatry has other
problems. Multiple physiologically distinct entities or
phenotypes are lumped together under a single diagnostic
label. For example, using the DSM diagnostic criteria for Major
Depressive Disorder (15), there are over 20 possible distinct
phenotypes of this single diagnosis. Patients with depression can
have insomnia or hypersomnia. They can have increased motor
activity or decreased motor activity. They can have weight gain
or weight loss. It is difficult to see how such a multi-faceted
presentation can represent a single diagnostic entity which would
benefit in the same way from the same medications and/or
treatments. Indeed, many experts agree that depression is not
simply one thing, despite the efforts of mainstream psychiatry to
classify it into a single illness category.
The inadequacies of DSM categorical diagnostic strategies
have been highlighted by the relative failures of multiple large
treatment trials, including the STAR*D, STEP-BD, and the
CATIE (16–19). These massive multi-million dollar clinical
trials largely showed meager clinical benefit of newer
psychotropic medications and a general lack of ability to make
and keep patients well. As Thomas Insel stated (20),
“current medications help too few people to get better
and very few people to get well.”
The STAR*D trial (16, 21) examined a sequenced protocol of
antidepressant medications for patients with depression who had
failed at least one prior medication trial in an open-label protocol
with no placebo control. In this large multi-center trial of over
2,876 patients, all of the patients were initially treated with
citalopram. Non-responders were then switched to a stepped
sequence of other medications. At step 2, patients were
prescribed either buproprion, sertraline, venlafaxine or
buproprion or buspirone augmentation of citalopram. At step
3, patients were prescribed mirtazapine, nortriptyline, lithium
augmentation or triiodothryonine augmentation. In step 4, non-
responders were randomized to receive tranylcypromine or a
combination of venlafaxine and mirtazapine. In addition to an
extraordinarily low final remission rate of 13% (22), STAR*D
demonstrated decreasing response rates, increasing rates of
intolerable side effects and increasing likelihood of relapse (23).
For example, of the 1,085 patients who had a positive response to
citalopram in Step 1, 92% experienced relapse within 12 months
despite continued pharmacotherapy.
As such, the STAR*D trial demonstrated: (1) the failure of a
DSM psychiatric diagnosis to predict an effective treatment and
(2) the overall failure of standard antidepressants to yield lasting
clinical benefit. Moreover, the STAR*D results forced study
researchers to acknowledge, “that major depressive disorder is
biologically heterogeneous, such that different treatments differ
in the likelihood of achieving remission in different
patients” (21).
By contrast, neuroimaging studies have revealed several
neurophysiological substrates for depression. Functional brain
scans, such as SPECT (single photon emission computed
tomography) or PET (positron emission tomography) have
shown that patients presenting with the same symptoms of
depression can have very different functional features
occurring in their brains (24). Indeed, some of the anatomic
circuits of depression and mood regulation have been revealed by
converging evidence from SPECT, PET, and fMRI studies of
depression, as well as the analysis of the effects of either
traumatic lesions resulting in depressive symptoms or surgical
interventions used to treat severe cases of depression (25, 26). A
network of brain regions have been revealed by convergent
neuroimaging findings, which includes the dorsal prefrontal
cortex, ventral prefrontal cortex, anterior cingulate gyrus,
amygdala, hippocampus, striatum, and thalamus, and together
contribute to the pathophysiology of depression (27–29). Experts
have emphasized that depression is the result of multiple
pathophysiological processes and the dysfunction of multiple
pathways (25, 30). Depression is not a singular disorder and is
unlikely to have a singular treatment.
The distinct subtypes of depression detected using functional
neuroimaging do indeed predict and demonstrate distinct
treatment responses. In a large proportion of depression cases,
decreased activity (and therefore metabolism and perfusion) of
the frontal lobes, the insular cortex, and the anterior cingulate
gyrus (25–30) is found. However, some patients with depression
have increased perfusion in the precuneus, which correlates with
rumination and self-criticism (31). In contrast, some patients
with depression also have decreased temporal lobe function.
Many patients with depression show increased thalamic activity
(metabolism or perfusion) (32). Portions of the thalamus have
direct connections to the amygdala, the seat of fear, and anxiety
(33). Functional neuroimaging, such as SPECT and PET, can also
predict who will respond to certain antidepressants. For example,
those who are likely to respond to SSRI antidepressants show
increased perfusion in the ventral frontal cortex and anterior
cingulate (34, 35). SSRI antidepressants often induce decreased
activity and perfusion in these areas, as well as in the thalamus. In
contrast, some patients with depression have markedly decreased
dorsal frontal cortex and medial frontal cortex activity and
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perfusion. These patients are less likely to respond to SSRI
medications, but may respond better to noradrenergic
antidepressants (29, 36). Treatment-resistant depression may
show markedly increased activity and perfusion in the
subgenual cingulate (30).
NEUROIMAGING COULD GUIDE THE
DIAGNOSTIC PROCESS—IF ONLY…
Ironically, in this age of heightened awareness of the importance
of the brain and its central role in the generation of the
symptoms, we associate with psychiatric disorders,
the American Psychiatric Association (APA) has taken the
position that neuroimaging has no role in Psychiatry. In 2018,
the APA published a position paper stating “neuroimaging has
yet to have a significant impact on the diagnosis or treatment of
individual patients in clinical settings” (37).
When the APA officially declared that using neuroimaging to
look at the brain has no clinical value in psychiatry, it took a
step backwards scientifically. As if to codify the aphorism, “The
Absence of evidence is evidence of absence”, the APA then
conveniently ignores an entire body of neuroimaging research
which will be elaborated below. It also took a giant leap backward
in terms of the evolution of the medical diagnostic process. It is
not an overstatement to say that an obvious step in the diagnostic
process inherent to all forms of medicine is to actually look at the
organ of medical concern. A surgeon would not think of
operating—even under the most emergent of conditions—
without first obtaining an image of the surgical region.
Cardiology uses SPECT neuroimaging as a cornerstone of the
diagnostic evaluation of the heart. The APA also took a step
backwards morally by denying patients a potentially better way
to arrive at the treatment plan. Is it truly better to guess or
depend upon intuition versus utilizing all possible forms of
diagnostic information at one's disposal? Are multiple failed
trials of antidepressants better for the patient?
The APA's claim that neuroimaging has not had a significant
impact on the diagnosis and treatment of psychiatric illnesses
seems to assume that functional brain neuroimaging can only be
helpful if it provides a pathognomonic “fingerprint” for a DSM
diagnosis. Notwithstanding the absurdity of expecting imaging of
the human brain to yield a hallmark of a disorder created by a
committee, issues of comorbidity, and the shared final
neurophysiological outcome of multiple “diagnoses” make it
highly unlikely logically that we will have neuroimaging
“fingerprints” for committee-created disorders.
Moreover, comorbidity (the presence of two or more
diagnoses) is the rule, rather than the exception in psychiatry.
Patients with ADHD frequently have comorbid anxiety,
oppositional disorders, or learning disorders (15, 38–40).
Patients with depression have a very high rate of comorbid
anxiety (15, 41). Patients with Post-Traumatic Stress Disorder
(PTSD), particularly veterans, often have comorbid Traumatic
Brain Injury (TBI) (42–46). These comorbid diagnoses cloud the
diagnostic process. The DSMV was not designed with the brain
in mind and has done little to adopt the lessons learned about the
neurobiology of psychiatric disorders. Furthermore, functional
aspects of the brain do not neatly fit into DSMV categories (15).
Perhaps most shocking is the fact that this official declaration
by the APA (37) was not open to debate. There were no hearings
of interested parties. There was no opportunity for rebuttal. The
leadership of the APA made a mandate. The mandate is that
Psychiatry will not look at the brain of patients as part of their
evaluation, diagnostic workup, and care. The mandate is to
ignore the changes in the brain—both positive and negative—
that could be induced by the prescribed treatments. The mandate
is to ignore that other physiological processes may be occurring
which masquerade as a DSM psychiatric diagnosis. The mandate
is to ignore a large body of medical evidence that neuroimaging
does improve psychiatric care. And in so doing, the leadership of
the APA is depriving themselves, psychiatrists, and the general
public of effective and promising functional neuroimaging
opportunities that could improve clinical care. Of great
concern is the fact that such a respected organization would
take a position that misleads the profession and denies
physicians and their patients a potentially useful adjunct in the
process of arriving at a treatment plan. This becomes especially
concerning in light of the opinions of experts in the field and the
supporting research that the DSM categorical diagnostic system
is clearly flawed—and we must look for a more brain-based
diagnostic system.
MISSED OPPORTUNITIES IN
PSYCHIATRIC NEUROIMAGING
As members of the International Society of Applied
Neuroimaging (ISAN), we cannot agree with the position of
the APA. Our clinical experience as psychiatrists, neuroimaging
specialists, nuclear medicine physicians, and experienced general
practitioners is that functional neuroimaging, using SPECT and/
or PET functional imaging, provides valuable insights into
patient diagnosis. We will now summarize the data that
support the use of SPECT and/or PET functional
neuroimaging in the diagnostic process, as well as in the
treatment monitoring process. In addition, we will demonstrate
how other pathophysiological processes can masquerade as
psychiatric conditions. Only by correctly determining the
absence of these confounding pathophysiological processes can
treatment be maximally effective.
Ultimately, we will demonstrate that functional brain imaging
with PET and SPECT has already proven itself valuable in the
psychiatric treatment of individual patients, and we will illustrate
how it can contribute to the advancement of the field,
going forward.
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THE INCONGRUITY BETWEEN DSM
DIAGNOSTIC CATEGORIES AND
NEUROIMAGING FINDINGS
Besides the case of depression, another example of the
incongruity between DSM diagnostic categorization and
neuroimaging data is the diagnosis of Attention-Deficit-
Hyperactivity Disorder (ADHD). There is overwhelming
neurobiological and neuroimaging evidence that multiple
forms of ADHD exist. A multitude of functional imaging
studies utilizing a diversity of modalities, including SPECT,
fMRI, PET, and quantitative electroencephalogram (qEEG)
repeatedly derived similar results in children and in adults.
Some of these studies, reviewed by Cherkasova and Hechtman
(47), showed reduced regional brain activity during a
concentration task. Areas such as the prefrontal cortex, orbital
frontal cortex, and caudate nuclei in some patients with ADHD
decrease activity during concentration. This is what we have
come to recognize as “typical” or “intrinsic” ADHD.
However, there are alternate neurobiological processes which
produce an ADHD-like phenotype. For example, abnormal
anatomy and function have been reported in the cerebellum of
some patients with ADHD. Others diagnosed with ADHD have
poorly functioning temporal lobes (47). Our significant clinical
experience has shown that patients with symptoms of ADHD
can also present with diffuse over-activity of the cerebral cortices,
involving not only the frontal lobes, but also the temporal and
parietal lobes. This clinical observation is supported by recent
research looking at subclasses of ADHD endophenotypes (48,
49). Neuroimaging data clearly argues there is more than one
form of ADHD. Moreover, comorbidity occurs with high
frequency in patients with ADHD. Those with ADHD
frequently have comorbid anxiety, oppositional disorders, or
learning disorders (24, 38, 39). Lastly, traumatic brain injury
(TBI) involving the frontal lobes can result in impulsivity,
impaired attention, reduced judgment, and other hallmark
symptoms which are indistinguishable from ADHD. It would
be foolish to expect an injured brain to respond in the same
manner as an intact brain.
Altogether, these observations argue that we should not expect
all patients with the diagnosis of ADHD to respond favorably to the
same medications. As we have previously described, alternate
endophenotypes of ADHD have been revealed by neuroimaging,
and the medication responses of these individuals is different. For
example, we have described patients who became agitated and
aggressive on stimulant medications (24). SPECT functional
neuroimaging revealed widespread over-activity throughout the
cerebral cortices—a finding inconsistent with intrinsic ADHD.
These patients respond favorably to anti-convulsant medications
with a reduction in hyperactivity, impulsivity, agitation,
aggressiveness, and inattention.
A second example of an alternate endophenotype in ADHD is
reduced temporal lobe function (47). These patients will often
demonstrate no evidence of frontal lobe deactivation during a
concentration task, but persistent or worsening temporal lobe
hypoperfusion with SPECT functional neuroimaging. Given that
acetylcholine is an important neurotransmitter in the temporal
l obe s , we have u t i l i z ed donepez i l (Ar i c ep t ) , an
acetylcholinesterase inhibitor for these patients. Donepezil was
shown in a small study to improve ADHD symptoms (50). In
patients with reduced temporal lobe function, donepezil
improves attention and academic performance (24).
A third and highly prevalent example of an alternate
endophenotype for presumptive ADHD is TBI involving the
frontal and/or temporal lobes. Among patients with TBI,
problems with attention and concentration occur in at least
50% of cases (51–54). Injury to the neurons of the frontal lobes
leads to neuronal dysfunction. While this can resemble the
decreased function of frontal lobe regions found in intrinsic
ADHD, it is unrealistic to expect these injured neurons to
respond to medication in the same manner as healthy neurons.
By the same token, toxic brain injury can also masquerade as
ADHD. Frontal lobe neuronal injury from a host of toxins and
other insults can lead to impaired attention and other symptoms
of ADHD. This will be explored in greater detail in the next
section. Suffice to say that one need only look to the headlines to
see evidence of the increase in diagnosis of ADHD in areas
afflicted by lead toxicity (55).
PATHOPHYSIOLOGICAL SUBTERFUGE—
HOW TOXICITY, INFECTION, AND
INFLAMMATION MASQUERADE AS
PSYCHIATRIC DIAGNOSES
An important underlying concept for diagnostic imaging in all its
forms is that imaging allows a clinician to eliminate possibilities
and narrow the differential diagnosis. This progression is central
to any medical diagnostic process. Physicians obtain laboratory
values to eliminate alternative explanations for a patient's
symptoms and focus in on the diagnosis. Similarly, physicians
order imaging studies to further eliminate alternate diagnoses
and close in on the actual diagnosis for that particular patient.
For example, if a patient presents with shortness of breath which
is worse with exertion, such as when climbing stairs, then a
diagnostic process is begun. Let us examine that process from
two perspectives and by comparing it to the symptom of anxiety.
First, we will approach this patient as a psychiatrist would.
Second, we will approach this patient in the manner that most
physicians in medicine would.
A psychiatrist will start by interviewing the patient.
Regardless of the primary symptom—shortness of breath or
anxiety, the psychiatrist might ask when does this happen?
What makes it worse? What makes it better? Are there any
associated symptoms? Perhaps, what does this mean to the
patient? Interestingly, a patient with shortness of breath may
often become anxious. After listening carefully, then psychiatrist
would then label the primary symptom as a diagnosis (shortness
of breath disorder or anxiety disorder) as a diagnosis. The
psychiatrist might pontificate upon the causes, rooted in
childhood trauma or recent losses or the psychiatrist might
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simply prescribe a medication based upon what was discovered
in the interview. At this point, the cause of the shortness of
breath (or anxiety) is still unknown, and therefore, the chances of
curing the ailment are quite small. Nonetheless, the patient leaves
with a prescription for a benzodiazepine and may indeed have
some transient relief of the symptoms of shortness of breath and
anxiety. Yet, the patient is no closer to a diagnosis, an effective
treatment, or a cure than they were when they walked into the
psychiatrist's office.
A physician in other medical disciplines will start by
interviewing the patient. Many of the same questions will be
asked. But then the physician digs deeper. The physician will
examine the patient, listen to the lungs, try to induce the
symptom (shortness of breath or anxiety) in the office, and
order laboratory tests. The physician will likely order imaging
studies—a chest X-ray, perhaps a cardiac stress test (a form of
SPECT scan), perhaps a V-Q scan to rule out pulmonary
embolus. Ultimately, with the combination of history, physical
exam findings, laboratory testing results, and imaging results, the
physician will arrive at a short list of diagnostic possibilities and
will ask more questions of the patient or order further tests to
arrive at a cause for the original symptom. Is the patient short of
breath due to pneumonia, bronchial obstruction, cardiac
insufficiency, or something else? Is the patient anxious due to
shortness of breath, cardiac insufficiency, paraneoplastic
syndrome or a dozen other possible etiologies? The treatment
would then be tailored to the etiological basis of the symptom. A
cure could be forthcoming.
We can hear our psychiatric colleagues scoff. “Most people
with anxiety have an anxiety disorder”, they would say. “Most
people with alternating high and low moods have bipolar
disorder”, they would add. Why go on a wild goose chase?
We can understand their incredulity. For decades, psychiatry
has not had to consider alternative etiologies for their diagnoses.
There was no challenge to the categorical DSM system; however,
now, if psychiatry is to move forward, it must challenge the
categorical DSM system and incorporate the findings of
evidence-based neuroimaging into psychiatry. In the way of a
brief example, following the advent of anatomical MRI, routine
assessment of first episode psychosis included a brain MRI or CT
scan. By the late 1990s this practice was largely abandoned with
the justification that the expense did not justify the return on
finding an organic cause (reviewed in 56). Unfortunately,
alternative etiologies such as toxicity or infection, likely did not
show up in anatomical MRI and were, therefore, missed.
Today, there is substantial evidence for the role of toxins and
infections, such as Toxoplasma gondii or viral infection, in
schizophrenia. There is growing evidence of immunological
dysfunction causing psychosis (57, 58). The changes in brain
function associated with these infections can show up on
functional SPECT scan. Newer PET tracers for brain
inflammation are now being explored. Thus, looking at the
brain with functional neuroimaging in cases of psychosis may
strongly suggest a treatable cause for the psychotic symptoms.
The functional brain scan may lead the physician to laboratory
studies, which definitively reveal an infection or inflammatory
process. As a result, a patient could be treated with appropriate
antibiotics or anti-inflammatories targeting the cause of the
disorder. Rather, than condemning a patient to a lifetime of
antipsychotic medications, which may or may not help, a more
biological approach might cure the patient.
Schizophrenia is not the only example of a disorder with
possible immunological or infectious causes. Significant evidence
supports the role of infections and inflammation in obsessive-
compulsive disorder, anxiety disorders, depressive disorders, and
possibly bipolar disorder. Recognizing the DSM diagnoses are
clusters of symptoms and not actual biological entities is essential
to being able to look for treatable causes of brain dysfunction,
which currently are lumped together into singular DSM
diagnoses. Neuroimaging can and does play a critical role in
this process. As Thomas Insel, stated:
Imagine deciding that EKGs were not useful because
many patients with chest pain did not have EKG
changes. That is what we have been doing for
decades when we reject a biomarker because it does
not detect a DSM category. We need to begin
collecting the genetic, imaging, physiologic, and
cognitive data to see how all the data—not just the
symptoms—cluster and how these clusters relate to
treatment response (13).
We will explore some of the biological and, therefore,
treatable contributors to psychopathology which can and are
visualized using functional neuroimaging.
AUTO-IMMUNE
It has long been recognized that auto-immune disorders, such as
systemic lupus erythematosus can cause neurological and
psychiatric symptoms. Over the past two decades, appreciation
has grown for a widening array of auto-immune disorders with
very specific psychiatric manifestations. For example, autologous
antibodies to epitopes upon the neurons of the basal ganglia can
be produced following a Streptococcal infection. The resulting
damage to the function of the basal ganglia can lead to severe
anxiety and obsessive-compulsive symptoms (59, 60). This
syndrome , r e f e r r ed to as Ped ia t r i c Auto immune
Neuropsychiatric Disorders Associated with Streptococcal
infections (PANDAS) has now been found not only in
children, but in adolescents and adults (61). In addition, it has
been found to occur following other non-strep infections (62,
63). The more generalized term for this condition is Pediatric
Acute-onset Neuropsychiatric Syndrome (PANS). The
symptoms include: abrupt onset of anxiety or obsessive-
compulsive symptoms, emotional lability or depression,
irritability, aggression, motor and sensory abnormalities,
urinary dysfunction, academic decline, and sleep disturbance.
A patient with one or more of these symptoms could be variably
diagnosed with obsessive-compulsive disorder, depression,
bipolar disorder, oppositional defiant disorder, intermittent
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explosive disorder, anger dysregulation disorder of childhood,
and/or generalized anxiety disorder (10). However, a functional
brain SPECT scan may reveal diffuse hypoperfusion throughout
the cerebral cortices and increased activity in the basal ganglia.
This pattern would not be expected for any of the psychiatric
diagnoses above. Rather, this finding signals a diffuse insult to the
brain, such as a toxic, inflammatory, or infectious attack.
INFECTIONS
A growing body of evidence suggests that infections with
cytomegalovirus (Herpes 5), Epstein-Barr virus (Herpes 4) or
Human Herpes virus 6 (Herpes 6) are responsible for a portion
of cases of depression and/or bipolar disorder (64–67). Prusty
and colleagues (65) examined samples of human cerebellum
from a brain bank for Herpes 6 DNA. Using immunofluorescent
labeling, followed by fluorescent in-situ hybridization (FISH), as
well as DNA amplification by polymerase chain reaction (PCR),
the group localized Herpes 6A and 6B virus in the tissue. Cell
type was confirmed by co-staining with immunofluorescent
markers specific to cerebellar Purkinje neurons and for glial
cells. The striking finding was that Herpes 6 DNA and signs of
DNA replication were found within neurons from human brains.
The distribution of Herpes 6-positive neurons was not uniform.
Among brains from patients with the diagnosis of depression
(N = 25), 53% were positive for Herpes 6B DNA, while only 24%
of those with bipolar disorder (N – 25) and 16% of control brains
(N = 50) contained DNA of the Herpes 6B virus. Prusty and
colleagues (65) have provided definitive evidence that Herpes 6
virus can reach the brain in a significant proportion of humans
and replicate therein. The group's findings also provide a strong
association between the presence of Herpes 6 DNA and mood
disorders. As yet, causality has not been demonstrated.
Clinical data do support, but also do not prove, a causal
relationship between Herpes viruses and mood disorders. For
example, Henderson (67) found high levels of antibodies against
Herpes 4 and Herpes 6 in adolescents diagnosed with treatment-
resistant depression. Anti-viral therapy with valacyclovir resulted
in marked improvement of fatigue and depressive mood
symptoms. Recently, Frye and colleagues (66) reported
increased levels of Herpes 5 antibodies in patients diagnosed
with bipolar disorder. SPECT functional brain scans of patients
affected by these types of infections reveal diffuse hypoperfusion,
a marker of infection, toxic injury, or sometimes inflammation.
The scans of such patients typically do not reveal increased
thalamic activity, a marker often associated with depression.
INFLAMMATION
Furthermore, the role of inflammation in depression is now
supported by a wealth of evidence. Experts now believe that
inflammatory processes underlie and contribute to depressive
pathophysiology in a significant proportion of cases (68–71).
These concepts grew from observations that medications which
reduced inflammatory processes had antidepressant properties.
For example, treating multiple sclerosis with powerful anti-
inflammatories was associated with reduction of depressive
symptoms (68). Conversely, treatment of hepatitis C with
interferon alpha, a powerful activator of an inflammatory
response, induces depression in roughly 20% of patients (72,
73). Work over the last decade has characterized the nature of the
inflammatory processes underlying depression and its possible
influence on the brain. Briefly, cytokines are elevated in a portion
of patients suffering from depression. In particular, tumor
necrosis factor alpha (TNFa), interleukin-2 (IL-2), interleukin-
6 (IL-6), interleukin-13 (IL-13), interleukin-18 (IL-18), C-
reactive protein (CRP), chemokine-2 (CCL2), and chemokine-
11 (CCL11) are elevated in depression based on multiple meta-
analyses (68, 71, 73). But how inflammatory cytokines induce
depressive symptoms remain incompletely understood.
There is evidence that TNFa alters endothelial cells which
make up the blood-brain barrier leading to increased
permeability. Thus, cytokines have access to the CNS and can
induce CNS inflammation. Elevated levels of TNFa and other
cytokines have been detected in the hippocampus and striatum
and can induce impairment of long-term potentiation in the
hippocampus leading to depressive symptoms (74). Cytokines
also appear to suppress the response to reward cues in the ventral
striatum (75). Efforts to reduce inflammation using anti-cytokine
medications have shown promise as anti-depressants.
Kappelmann and colleagues (76) recently summarized the state
of the field in a meta-analysis. For example, TNFa antagonists
had anti-depressant effects in a subset of patients who had
elevated CRP levels (69, 70, 76). The IL-6 antagonist,
tocilizumab, also shows anti-depressant qualities (76).
Similarly, rituximab, an antibody which inhibits B cell activity,
can induce decreased fatigue and improved mood in patients
treated for rheumatoid arthritis (73). Recently, the antibiotic,
minocycline, which has immunomodulatory effects, has been
shown to improve depressive symptoms (77). Altogether, several
meta-analyses now support the role of inflammation in a portion
of depression cases. Treating the inflammation could potentially
eliminate or “cure” the depressive symptoms. However, how
would the psychiatrist ever know to treat for inflammation?
Inflammation is unlikely to be revealed by an interview question.
The inflammation that underlies depression in these cases
often leads to diffuse hypoperfusion on functional SPECT brain
scan. More striking are cases of marked increased perfusion in
early inflammation which presents a paradoxical finding not
encountered in cases of depression. Recently developed, but as
yet not commercially available PET markers for inflammation
will show marked increased uptake in these cases (70, 78). As
described above, this is distinct from the pattern of increased
thalamic activity which often characterizes depression. Treating
a patient so affected with a serotonin reuptake inhibitor or other
antidepressant is unlikely to provide optimal response. In
contrast, treating the inflammation may eliminate the
depressive symptoms. However, for the psychiatrist to know
which approach to utilize, he/she would benefit from first
looking at the brain function.
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GUT-BRAIN INTERACTIONS
While controversial, the role of the gut and gut bacteria
(microbiome) is gaining appreciation as a contributor to
psychiatric symptoms, including mood symptoms. The various
yeasts and bacteria species that make up the microbiome live in a
delicate balance. Antibiotics, excessive sugar, alcohol,
environmental agents, and foreign infections can destabilize
this balance. Overgrowth of certain bacteria or yeast species
can damage the tight-junctions of the lining of the
gastrointestinal (GI) tract leading to abnormal serum levels of
polysaccharides and other molecules normally confined to the
intestinal tract. Inflammatory responses within the GI tract can
lead to pathological irritation of the vagus nerve with resulting
depressive symptoms (79, 80). GI tract inflammation appears to
also be capable of inducing CNS inflammation (79).
While as yet poorly studied, many clinicians are utilizing
antifungals for depression, anxiety, schizophrenia, behavioral
dysregulation, and autism (81, 82). While skeptical, the authors
have experience with patients whose depression, agitation,
irritability, and manic-like mood symptoms improved with
elimination of sugars and a course of probiotics and
antifungals. This emerging field is often missed in interview
and abnormal functional brain scan patterns could lead the
psychiatrist to alternative organic causes, which might include
gut-brain dysfunction.
ILLUSTRATIVE CASE 1
We offer an illustrative example with the understanding that the
plural of anecdote is not data. A male college student presented
for evaluation due to problems with attention, feelings of anxiety,
getting confused in social or high-stimulus situations, getting lost
or feeling uncertain about his route when going to class, and
academic decline. The outside psychiatrist diagnosed the young
man with Bipolar Disorder, Social Anxiety Disorder, and ADHD.
After several medication trials which seemed to have no benefit
or make the patient feel worse, the patient withdrew from college
and returned home. As the patient worked in psychotherapy
with the psychiatrist and after the patient became irritable and
agitated on a psychostimulant, the psychiatrist added the
diagnosis of Borderline Personality Disorder.
The patient came to the clinic of one of the authors (TAH) for
a second opinion. Notably, the young man had gone from being a
FIGURE 1 | Tc-99m-HMPAO perfusion SPECT scan data presented in surface rendering. The color scale is scaled relative to the patient's mean cerebral perfusion.
Mean blood flow (72%) is in yellow. Color shifts occur at approximately every 0.5 SD (3%) relative to the patient's mean. Diffuse cortical hypoperfusion (green and
blue) is clearly evident.
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socially active and motivated high school student to being
reclusive, lethargic, unmotivated, and demoralized. Careful
interview and additional symptom questionnaires revealed
profound fatigue, unrefreshing sleep, and low-level confusion.
The academic failure, getting lost or confused about routes, and
the inattention were more consistent with “brain fog,” a
colloquial term for mild cognitive dysfunction.
A search for a biological cause of the patient's symptoms was
clearly in order. A SPECT functional brain scan was ordered. The
result is presented in Figure 1. The SPECT scan revealed diffuse
hypoperfusion, suggesting toxic, infectious, or inflammatory
processes. The patient denied substance abuse, including the
huffing of chemicals. His toxicology screen was negative. Viral
antibody levels were ordered, and these revealed no elevation of
antibody levels for Herpes 1,2,4,5, but elevated antibodies to
Herpes 6. The C-reactive protein level was normal. The patient
was started on antiviral therapy (67). However, after four months
there was little change in his symptoms. Perhaps the first
psychiatrist was correct. The patient had bipolar disorder and
borderline personality disorder.
Yet, the SPECT scan told a different story. Therefore, testing
was done for Borellia, Bartonella, and Babesia infections. While,
the patient was negative for Lyme's disease, he was positive for
Bartonella henselae and Babesia duncani. Antibiotic therapy was
started. Within two months, the patient made a remarkable turn-
around. Anxiety diminished. Concentration and focus improved.
His energy and motivation improved. He felt clear-headed and
could now recognize how “foggy” he had been. The patient got a
part-time job and resumed college classes. Rather than being
condemned to a lifetime of powerful psychotropic medications
with considerable potential side effects and diagnostic labels
which carry considerable negative connotation, the patient
underwent a course of antibiotic therapy and returned to a
normal life. Without the SPECT scan, we would not have been
guided to look for an infectious cause. Multiple interviews by
psychiatrists had missed these infections. No DSM-guided
interview question would have prompted a psychiatrist to look
for these infections. Without neuroimaging, the diagnosis would
have been missed, and the treatment would have been incorrect.
THE SINGLE MOST COMMON
BIOLOGICAL CAUSE OF PSYCHIATRIC
SYMPTOMS
Not surprisingly, the single most common masquerader of
psychiatric disorders is TBI. Brain trauma irrefutably leads to
disruption of the function of the affected portion of the brain.
Since the brain is highly organized with each structure involved
in a specific function, the functional disruption depends on what
part of the brain is injured. Damage to the parietal lobes can
affect visuospatial processing, spatial orientation, and language/
writing abilities. Damage to the temporal lobes, which is among
the most common injuries (83), leads to memory difficulties,
learning difficulties, and emotional dysregulation. Damage to the
frontal lobes, the single most common area to be injured (83),
leads to impaired judgment, impaired concentration, fatigue,
depression, and a host of other challenges.
The role of functional neuroimaging and brain SPECT, in
particular, extends beyond showing the location and extent of
local abnormality at the site of impact, which is typically seen as
areas of hypoperfusion. Indeed given the brain's capability to
compensate by recruiting other structures both proximal and
distal to the impact site, one may be faced with areas of higher
than normal perfusion, as well. Such areas may often
overcompensate (over-recruit) and can present as localized
areas of extreme hyperperfusion, frequently at distance from
the site of impact. The importance of this is that such
hyperperfused structures may generate and sometimes
dominate the patient's symptoms and thus need to be
considered when establishing a tailored treatment plan (84).
Alternatively, TBI may present with diffuse perfusion changes on
brain SPECT. This can be seen, for example, in MVA where there
has not been direct contact between skull and hard objects, but
only effects of significant acceleration/deceleration. In the
context of clinical history this type of diffuse brain SPECT
pattern can be most helpful in the process of evaluating and
treating patients with TBI (84).
The link between TBI and psychiatric symptoms is well-
characterized. For example, over 40% of patients who experience
a concussion (also known as mild TBI) will develop depression
over the subsequent year (85, 86). Other conditions may develop
as well. Concussion and TBI can lead to depression, suicidal
ideation, anxiety, irritability, anger outbursts, relationship
problems, irrational or socially inappropriate behaviors,
cognitive changes, and impaired memory. How does a
psychiatrist differentiate these symptoms from the symptoms
of Depression, Anxiety, Bipolar Disorder, Post-Traumatic Stress
Disorder, or Dementia? There is no single interview question
that will differentiate TBI from any of these diagnoses.
Questionnaires designed to assess psychiatric disorders often
have tremendous overlap with symptoms of post-concussive or
chronic TBI. For example, the Zung Depression Scale (87)
assesses disrupted sleep, mental clarity, fatigue, irritability,
decision making, and anhedonia—all symptoms found in
patients with TBI. Similarly, the Zung Anxiety Scale (88)
assesses nervousness, tremor, headaches, dizziness, tingling in
the limbs, and disrupted sleep—all symptoms common for
patients with TBI. Several of the question items within the
Clinician-Administered PTSD scale (89) can be symptoms of
TBI, such as sleep difficulties, poor concentration, memory
difficulties, social isolation, anhedonia, and irritability.
Naturally, including questions specifically about TBI in all
psychiatric interviews will increase the likelihood of identifying a
patient who may have TBI masquerading as a psychiatric
disorder. Caution is warranted as often patients with TBI and
anterograde amnesia will not recall a head injury when asked the
first time. Only with multiple inquiries into a history of head
injuries, might a persistent clinician get a positive answer. At this
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point, the clinician might seek functional neuroimaging to clarify
the presence, location, and the magnitude of abnormality and its
contribution to the patient's symptoms.
The situation has particular significance for the nation's
veterans. TBI and PTSD are both common in military
populations, creating a particularly thorny challenge to
distinguish the two conditions (46). These two conditions may
overlap by as much as 33% to 42% (90). Recently, the Veterans
Administration facilities revealed 73% of patients reporting TBI
were comorbid for PTSD (91). For patients who have both TBI
and PTSD, which generate many of the same symptoms, the VA
acknowledges that the patient is often diagnosed with only one of
the conditions (42–45). Indeed, the VA admitted in November
2017 that it had misdiagnosed tens of thousands of veterans (92).
Brain injury alters the way the brain responds to its
environment, to stressors, and to medications. There is no
reason to expect patients with TBI to respond to medications
in the same way as those who have endogenous depression. The
pharmacological treatments for TBI are largely targeted towards
symptoms rather than the cause of neurological disruption (93,
94). These pharmaceuticals include the serotonin reuptake
inhibitors, serotonin-norepinephrine reuptake inhibitors,
benzodiazepines, mood stabilizers, and atypical antipsychotics
(93, 94). Several studies have examined the benefit of sertraline
for post-TBI depression (95–97). Other serotonin reuptake
inhibitors also have been examined (94). The results are not
consistent, and those with a history of TBI are more likely to be
deemed treatment-resistant.
Modulation of the dopaminergic system may improve
alertness, attention, and cognitive processing speed. The
stimulants are most commonly used for this purpose.
Amantadine and bromocriptine may also increase dopamine.
Studies of these agents have shown reduced abulia, anergia, and
anhedonia in those with TBI (98, 99). However, amantadine may
cause confusion, hallucinations, and hypotension. Small studies
have suggested some benefit of bromocriptine on cognitive
function (100, 101).
While antidepressants can be useful in managing some of the
symptoms of TBI, the prescribing of benzodiazepines to those
with TBI can impede function or be dangerous (94, 102, 103). Of
note, antipsychotics have been shown to impede recovery or be
dangerous in clinical studies and animal models of TBI (104,
105). Yet, a factor associated with an increased likelihood of a
veteran being prescribed an antipsychotic or a benzodiazepine is
the diagnosis of TBI. For example, 41% of veterans with PTSD
were prescribed benzodiazepines, while those with both PTSD
and TBI had a 67% chance of being prescribed a benzodiazepine.
Similarly, antipsychotics were prescribed to 25% of veterans with
PTSD, but 40% of those with both PTSD and TBI (103). Other
treatments for PTSD, such as transcranial magnetic stimulation,
can be dangerous in TBI due to induction of seizures (106).
Hyperbaric oxygen treatment has been explored as a
treatment for TBI. Hyperbaric oxygen therapy is neither a
completely benign treatment, given the concerns of oxygen
toxicity (107, 108), nor is it a clear treatment in that the
placebo condition of moderate hyperbaric room air also
effectively improves cognitive function (109). The most
carefully performed study compared a group in a cross-over
design with both an interval of null treatment and of hyperbaric
oxygen at 100% oxygen and 1.5 atmospheres (110). They
described improvement in many of the symptoms associated
with persistent TBI including headache, tinnitus, vision
disturbance, memory dysfunction, and impaired cognitive
function. Hyperbaric oxygen remains a controversial area both
in acute TBI (107–109) and for some in chronic TBI (111, 112),
while others have found hyperbaric oxygen is quite helpful as a
treatment for TBI (113).
Unfortunately, little has been found to reverse the damage of
TBI or repetitive concussion which is the root cause of residual
cognitive and psychological impairment following TBI (94). One
potential avenue of treatment for TBI is infrared light, which has
shown promising data in a number of applications (114, 115).
Transcranial application of near-infrared light using multi-Watt
infrared laser has shown efficacy in treating multiple symptoms
of TBI, including depression, anxiety, sleep disruption,
hyperarousal, memory problems, and sleep disruptions (42–45,
51, 116).
ILLUSTRATIVE CASE 2
A second case illustrates this situation well. Based on a review of
the chart notes prior to the patient coming to one of the author's
clinic, the patient presented in the following manner. A young
adult male with the diagnosis of depression was referred to a
well-seasoned psychiatrist. The referral from a psychologist was
prompted by the findings on psychological testing that suggested
a Bipolar-type mood disorder. Specifically, the patient was given
a Minnesota Multiphasic Personality Inventory (MMPI) which
showed an introverted man with low morale and depressed
mood. The MMPI also indicated a preoccupation with feeling
guilty and worthless, that he deserves to be punished for the
wrongs in his life, that he struggles to manage daily affairs, and
has poor memory, poor concentration, and no energy for life. He
scored high on certain schizophrenia subscales, as well as on
introversion and depression subscales. The psychiatrist
conducted an evaluation interview and elicited statements
consistent with depression, difficulty concentrating, and social
withdrawal. A history of a trial of citalopram for depression and a
low dose of risperidone for “possible Bipolar Disorder” was
elicited. The psychiatrist inquired about medical problems, but
did not ask specifically about TBI. After thirty minutes, the
psychiatrist diagnosed the patient with Major Depressive
Disorder, Social Anxiety Disorder, and Somatoform Disorder.
He was prescribed citalopram. Later, he switched the patient to
fluoxetine and then added mixed dextroamphetamine salts.
The patient continued on this regimen for over two years, but
not really feeling much better than he had at baseline. He then
went to another psychiatrist for a second opinion. In the sixty
minute evaluation interview, the second psychiatrist elicited a
history of a TBI, but did not pursue it further. The patient was
switched from fluoxetine to buproprion and continued on the
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stimulant medication. Yet, the patient remained socially isolated,
moderately depressed, amotivated, pessimistic, and resigned to a
meager life of solitude. He worked as a landscaping assistant, but
did not socialize outside of work with peers or coworkers. He
avoided family functions because it was too over-stimulating. He
struggled with memory issues and difficulty making decisions.
Three years later, he came to one of the authors for a third
opinion. In this interview, the details of the TBI were explored in
more detail. The patient reported he had been in a high speed
collision at age 17 and had been thrown through the windshield.
He reported that he had been unconscious off the road for some
time before he was found. He reports that he has no recollection of
the accident or the events for many weeks afterwards. Moreover,
he has no recollection of his childhood or his high school years.
His family has told him that he had to relearn how to use eating
utensils, read, write, and talk. The history was sufficient to warrant
getting neuroimaging to determine what parts of the brain were
injured. Figure 2 shows the patient's SPECT scan.
The case illustrates not only the degree to which TBI can
affect a person's life, but also the unfortunate tendency among
psychiatrists to underappreciate the degree to which TBI can
generate psychiatric symptoms. The patient shows damage to the
frontal and anterior temporal lobes, as well as to the insular
cortices. Thus, the symptoms of low motivation, struggles with
decisions, poor concentration, depression, anxiety, low energy,
impaired memory, and introversion all make sense. Add to this
neurophysiological insult, the loss of all memories prior to the
accident, and the patient begins to look like an entirely different
case. An SSRI and a stimulant are unlikely to fix this
patient's symptoms.
FUNCTIONAL NEUROIMAGING CAN AID
THE DIAGNOSTIC PROCESS
While the position of ISAN is not that SPECT or PET functional
neuroimaging replaces the diagnostician, it is our position that
functional neuroimaging can aid and inform the diagnostic
process and resulting treatment plan. Can neuroimaging
provide a pathognomonic imaging result (a fingerprint, if you
will) for each DSM condition? No, but it can eliminate several
possibilities and lead one closer to a definitive conclusion.
Functional neuroimaging can offer clues and information
about psychiatric disorders and their comorbid conditions.
Functional neuroimaging helps clinicians to unravel complex
cases. For example, ruling out toxic exposure or TBI can be highly
valuable in the differential diagnosis of complex cases. The ability of
FIGURE 2 | Tc-99m-HMPAO perfusion SPECT scan data presented in surface rendering. The color scale is as in Figure 1. Bilateral frontal and temporal
hypoperfusion (green and blue) is clearly evident and is consistent with traumatic brain injury.
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SPECT neuroimaging to differentiate TBI from PTSD not only
meets the APA criteria, but offers hope to tens of thousands of
veterans who suffer from one or both disorders (42–45). As a second
example, if a perfusion SPECT scan shows a diffuse pattern of
decreased function, ADHD become much less likely and systemic
effects such as metal (117), mold (118), or other (119) toxicity,
carbon monoxide poisoning (120), or infection (121) become more
likely. Rather than treating the patient with a stimulant, a clinician
would be directed by the scan results to seek a cause for the brain
dysfunction, as described above.
There are diagnoses for which SPECT and/or PET functional
neuroimaging have proven their value for thorough evaluation
and the guidance of effective treatment strategies. Indeed, the
sensitivity and specificity of SPECT and PET meets or exceeds
the APA recommendations in a number of disorders.
WELL-ESTABLISHED DIAGNOSTIC ROLES
FOR SPECT AND PET
First, numerous published, peer-reviewed studies by
independent investigators show that both fluorodeoxyglucose
positron emission tomography (FDG-PET) and SPECT meet the
criteria set by the APA in diagnosing Alzheimer's disease (122).
FDG-PET and SPECT both have sensitivity and specificity in the
diagnosis of Alzheimer's disease between 82% and 89% (122).
Moreover, FDG-PET and SPECT are superior to amyloid
imaging in the differential diagnosis of the various forms of
dementia (24, 122). To be specific, a positive amyloid scan can
reliably be considered evidence of Alzheimer's disease or its
precursor (sensitivity = 89%; specificity = 87%) (123). However,
the non-specific binding in amyloid scans increases dramatically
with age to over 40% in patients over 80 years (122, 124). Thus,
the specificity of amyloid imaging declines dramatically with age.
Furthermore, if an amyloid scan is negative, then the patient
presumably does not have Alzheimer's disease, but it is
impossible to differentiate among the alternative forms of
dementia with an amyloid scan. FDG-PET and SPECT are
superior in this regard (24, 122) and can provide clear
evidence to aid in the differential diagnosis.
Second, brain perfusion SPECT (125, 126) can readily
distinguish ADHD from controls. Indeed, SPECT scans
differentiated children who were highly likely to respond
favorably to stimulants from non-responders (125). As
illustrated above, SPECT neuroimaging can provide important
clues which aid in the clinical management of presumptive
ADHD cases, which do not respond in a typical fashion to
stimulant medications. Nonetheless, Lee and colleagues (125)
characterized a reasonably sized sample of 40 medication-naïve
children with ADHD compared to 17 controls using SPECT plus
statistical parametric analysis before and after treatment with
methylphenidate. Statistical analysis confirmed that subjects with
ADHD showed decreased perfusion (activity) of the prefrontal
cortex and middle temporal gyrus, but showed increased
perfusion (activity) in the somatosensory cortex and anterior
cingulate gyri, compared to controls. After treatment with
methylphenidate, ADHD subjects showed increased perfusion
of the prefrontal cortex relative to their own pre-medication
scans. Perfusion in the somatosensory cortex and striatum was
reduced (125). These SPECT studies have been confirmed by
numerous fMRI studies which have found similar impairment of
the fronto-striatal networks. For example, Pliszka and colleagues
(127) found that adolescents with ADHD (N = 17) failed to show
increased perfusion (activation) in the anterior cingulate
bilaterally and the left ventrolateral prefrontal cortex during an
inhibitory task (Stop Signal Task) compared to 15 age-matched
controls. Smith and colleagues (128) similarly described
decreased perfusion in the left rostral mesial frontal cortex
during one interference-type concentration task and decreased
perfusion in the bilateral inferior prefrontal (right more
significant than left) and temporal lobes during a switch
task (128).
Third, perfusion SPECT brain function neuroimaging is very
useful in differentiating TBI from controls and TBI from PTSD
(42–45, 129, 130). Notably, there is tremendous overlap (33% to
42%) (90, 91) between the clinical presentation of TBI and PTSD
in veterans. As discussed above, diagnostic instruments routinely
used by the Veterans Administration (VA) are neither sensitive,
nor specific. For instance, several of the symptoms assessed by
questions in the Clinician-Administered PTSD scale (89) could
be a result of TBI, such as sleep difficulties, irritability, poor
concentration, and memory difficulties. Using perfusion SPECT
neuroimaging, TBI and PTSD can be differentiated with a
sensitivity of 92% and a specificity of 85% based on a study of
196 veterans (129). Furthermore, these results were replicated in a
separate civilian population of over 24,000 individuals (130).
These findings certainly meet the APA's criteria for a psychiatric
“biomarker,” which they declared should have greater than 80%
sensitivity and specificity and be replicated with independent data.
Fourth, independent groups have shown that SPECT
neuroimaging (or its equivalent) improves treatment outcomes.
In a six-month open-label outcome study of 500 patients, SPECT
scans were associated with improved clinical outcome (23). Of
the 500 patients, 231 were diagnosed at baseline with depression
and had overall tried 5.45 different medications and seen four
prior psychiatrists. After six months of multi-modal treatment
(pharmacology, nutrition, lifestyle change) guided by SPECT
scan results, over 56% of the depressed patients had a greater
than 50% improvement in depression levels as assessed by the
Beck Depression Inventory (23). Quality of life measures also
were markedly improved (85%) in patients whose treatment was
guided by functional neuroimaging findings (23).
Similar results were obtained in a smaller study by a different
group (36). A group of 28 patients who underwent SPECT
functional neuroimaging at baseline and received treatment
guided by the results of the SPECT scans were compared to a
matched group of 28 controls who received treatment guided
only by clinical acumen. The information derived from the
SPECT scan, in combination with clinical information,
determined the course of pharmacological treatment or
changes to the pre-existing pharmacological treatment. After a
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course of treatment, patients underwent a repeat SPECT scan.
Duration of treatment was variable in this open-label,
naturalistic study (mean = 17 months). The primary outcome
measure was GAF, and no additional quantitative assessments
were routinely included. Nonetheless, improvements in GAF
were greater for those patients whose treatment was guided by
SPECT scan results (13.8 vs. 8.6; p < 0.01).
Cerebral perfusion can also be measured using arterial spin
labeling in an MRI and was recently shown to predict SSRI
response (131). In a sample of 231 patients with Major
Depressive Disorder, increased perfusion in the putamen,
anterior insula, inferior temporal gyrus, parahippocampal
gyrus, inferior parietal lobule, and the orbitofrontal cortex
predicted a positive response to the SSRI antidepressant
sertraline (131). Further studies of the value of cerebral
perfusion neuroimaging, using SPECT and arterial spin
labeling in guiding effective treatment are ongoing.
LIMITATIONS OF SPECT AND PET
IMAGING
We certainly do not want to whitewash functional neuroimaging
and acknowledge that there are some limitations and areas of
potential concern. If neuroimaging is accepted and adopted by
the psychiatric community, then several of the current limitations
will resolve as part of the evolution of the use of neuroimaging as a
modality in the field. These malleable current limitations include: 1)
reluctance of insurance companies to cover the procedure, 2)
unrealistic expectations of a pathognomonic “fingerprint” for a
DSM diagnosis on the part of patients and physicians, and 3) the
lack of comfort, understanding, and familiarity among physicians
with the relationship between neuroimaging findings and
neuropsychiatric conditions as elaborated in this review. We
foresee this progression mirroring the process by which other
neuroimaging modalities, the DaTscan for Parkinson's disease and
the amyloid scan for Alzheimer's disease, have gained acceptance by
the insurance industry. As neuroimaging finds its place as a tool in
the evaluation and ongoing assessment of neuropsychiatric patients,
greater cooperation between nuclear medicine physicians and
psychiatry physicians will evolve naturally. Further replications of
the work by Thornton and colleagues (36) and others to definitively
demonstrate that neuroimaging improves treatment outcomes
would likely attract the attention of third-party payers. In fact,
SPECT neuroimaging arguably meets the criteria set forth by the
Centers for Medicare & Medicaid Services for Coverage with
Evidence Development classification and providing Medicare
coverage for psychiatric indications. SPECT is already covered by
Medicare for TBI and dementia.
Education of physicians will be essential in this process of
introducing neuroimaging into mainstream psychiatry. This is
no different from the situation of introducing the first atypical
antipsychotic, the first dopamine partial agonist, or transcranial
magnetic stimulation. The expectations and the understanding of
both patients and physicians will come through education.
Thematic to this review has been highlighting the disparity
between the categorical system of diagnosis and the
neurobiological findings.
In our collective clinical experience, patients tend to be less
interested in the “diagnosis,” compared to physicians. Rather,
patients tend to be most interested in learning what can be done
for their condition, whatever it might be. SPECT and PET
functional neuroimaging helps the patient by revealing the
functional substrate of their psychiatric/psychological
symptoms. There are two very fascinating outcomes we have
observed. First, the patient, as well as their family, engages in less
blaming and criticism since they now see the symptoms as the
product of disrupted neurophysiology. Second, the patient often
demonstrates improved compliance with treatment.
Since both SPECT and PET neuroimaging are nuclear
medicine techniques, which involve radioactive tracers, there is
an associated risk of radiation exposure. By contrast, MRI and
functional MRI do not expose the patient to radiation.
Unfortunately, these non-invasive MRI modalities have failed
to yield clinically useful diagnostic approaches (15, 37). A brain
FDG PET scan on average carries a 700 mRems exposure (132),
while a head CT scan can lead to an exposure of 800 to 900
mRems (132), depending on the imaging protocol. A perfusion
SPECT scan of the brain carries a 640 mRems exposure (132).
This exposure is approximately two times the range of typical
background exposure (290–390 mRems) from the natural
environment and modern technology, such as smoke detectors,
televisions, computers, and air travel (133). The radiation
exposure from a SPECT scan is less than that of cardiac
fluoroscopy for stent placement, abdominal fluoroscopy, or
helical cardiac CT imaging (134). A pediatric SPECT scan uses
considerably less tracer and yields an average exposure of 220
mRems (134). This is less than a CT scan, abdominal
fluoroscopy, or other pediatric fluoroscopic procedures (134).
Many physicians lack a frame of reference for these numbers and
concerns around any radiation exposure permeate medical
thinking. However, the fear that any amount of radiation
exposure can lead to adverse outcomes is not actually supported
by the medical literature (134). Without delving too deeply into the
theoretical debate, the question boils down to whether or not there
is a Linear No-Threshold Model or a Threshold Model for risk
associated with radiation exposure. The proponents of the Linear
No-Threshold Model hold that all radiation is potentially harmful,
as summarized by Howe and McLaughlin (135) and the BEIR V
report (136). However, on close examination, the studies often cited
as supporting the Linear No-Threshold Model, in fact, do not
support the Linear Model. In particular, Howe and McLaughlin
(135) reports increased cancer rate among women exposed to chest
fluoroscopy, but these data clearly demonstrate a decreased risk at
doses below 2000 mRems (135, 137). Likewise, a study by the
International Agency for Research on Cancer (138) involving
95,673 subjects demonstrated a negative correlation between low-
level radiation exposure and cancer risk. Indeed, the cancer risk was
increased only at radiation doses exceeding 4,000 mRems (138).
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Additionally, there is extensive evidence against long-term
risk associated with low dose radiation exposure (139–141). For
example, Saenger and colleagues (139) reported on a three year
follow-up of 18,379 patients treated with radioactive iodine for
hyperthyroidism with an average dose of 10,000 mRem to bone
marrow, relative to non-irradiated subjects, and found no
increased rate of leukemia. Long-term risk does not appear to
be elevated in children either. For example, Ron and colleagues
(140) described a cohort of 11,000 patients under the age of 15
years treated with radiation for tinea capitis and receiving an
average dose of 9,300 mRems (range, 4,500–50,000 mRems).
Compared to 16,000 controls at 22-year follow-up, there was no
difference in the rate of leukemia. In summary, the risk of cancer
or radiation injury associated with SPECT scans with a radiation
dose of only 608 mRems or PET scans at a radiation dose of 700
mRems remains hypothetical, as there is no published data
demonstrating an actual quantitative increase in cancer rates
associated with nuclear brain scans.
But what do the experts say about the overall risk of
undergoing a SPECT scan or a PET scan? A leading authority
on the subject of medical radiation exposure, Dr. Michael
Devous, has stated in several settings (142, 143),
“…that there are no data that have ever demonstrated
any harm to humans by radiation exposures at
diagnostic imaging levels (emphasis added). In fact,
current data support the presence of radiation
hormesis; that low levels of radiation exposure
induce beneficial effects of cellular repair and
immune system enhancement….Therefore, it should
be concluded that neither SPECT nor PET brain
imaging procedures are associated with any
particular risk over activities of daily living and
certainly should not be considered to be any more
risky than MRI or any of its associated functional
imaging derivatives”.
Along the same lines, the Health Physics Society in their 2004
and 2009 position papers (144) states,
“the Health Physics Society recommends against
quantitative estimation of health risks below an
individual dose of 5,000 mRems in one year or a
lifetime dose of 10,000 mRems … There is
substantial and convincing scientific evidence for
health risks at high-dose exposure. However, below
5,000 to 10,000 mRems (which includes occupational
and environmental exposures) risks of health effects
are too small to be observed or are non-existent”.
Similarly, the American Nuclear Society in its 2001 position
paper (145) states,
“There is insufficient scientific evidence to support the
use of the Linear No Threshold Hypothesis (LNTH) in
the projection of effects of low-level radiation.”
CONCLUSION
One could assume that the introductory sentence of the APA
position paper clearly signals the fear that drives the APA's
position (37):
“In response to claims being made that brain imaging
technology had already reached the point at which it
could be useful for making a clinical diagnosis and for
helping in treatment selection in individual patients”
If we reframe this “driving fear” as trepidation about
abandoning a categorical system of diagnosis and undertaking
the process of learning about and of transitioning to a clinically
useful diagnostic process that includes functional neuroimaging,
then the resistance of the APA becomes more understandable.
The present psychiatric clinical disorder system, DSMV, was
never designed to enable the psychiatrist to envision the
underlying neurobiological function of the disorders that they
are “seeing” clinically. The challenge of pulling away from a
categorical system and transitioning to one that takes infections,
inflammation, brain injury, toxic injury, and possibly even
microbiome influences, into account might be chilling to the
average psychiatrist, as well as to the leadership of the APA. But,
as Thomas Insel (13) quoted Craddock and Owen (146) stated,
“at the beginning of the 21st century, we must set our
sights higher”.
Functional neuroimaging is and must continue to be at the
center of efforts to unravel the neurobiology of psychiatric illness
and provide help for its treatment.
Those of us who use neuroimaging in our daily clinical care of
patients, we have come to appreciate what is only recently being
voiced by the research community, namely that functional
neuroimaging reveals biotypes within psychiatric illness that
both subdivide and cross DSM categorical boundaries. In his
introduction to the July 2019 issue of the APA's lead journal
which was devoted (ironically) to neuroimaging in the wake of
the APA edict, Kalin (147) called upon Psychiatry to develop
brain-based, data-driven protocols for diagnosis and treatment
targeting the structurally and functionally distinct neural
targets to:
“significantly improve the lives of many of our patients
who continue to suffer”.
In the same issue, Etkin (148) described the “missed
opportunities” of neuroimaging in Psychiatry as including not
recognizing earlier the absence of a neural signature for
categorical DSM diagnoses. He encouraged functional
neuroimaging studies with larger N's and a perspective of
seeking indicators of treatment response, similar to his work
with cerebral perfusion described above. He also advocates for
data sharing across centers and the increased use of the single-
patient, multiple-repeated-measures study design to elucidate
neural mechanisms underlying key symptoms and key treatment
responses. Etkin stated: (148)
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“we may be at an important inflection point for
the field”.
Insel had recognized and advocated for this inflection point
almost two decades earlier stating: (149)
Patterns of regional brain activity associated with
normal and pathological mental experience can be
visualized … and ultimately, biomarkers for mental
disorders may not be proteins or neurotransmitters
but may emerge from neuroimaging (functional
magnetic resonance imaging (fMRI), single photon
emission computed tomography (SPECT), etc.
Logically, if these are disorders of brain systems,
then the visualization of abnormal patterns of brain
activity should detect the pathology of these illnesses.
The members of ISAN renew their call upon the APA and
psychiatrists everywhere to re-examine functional brain imaging
in Psychiatry with inclusion of SPECT and FDG-PET research
and their already published clinical utility. Rather than set
unrealistic APA expectations for a neuroimaging biomarker for
a psychiatric disorder and its comorbid conditions, we encourage
the APA to appreciate the already-recognized value of using
functional brain imaging in the incremental steps of a clinical
differential diagnosis and to elucidate biotypes underlying key
symptoms rather than seeking DSM categorical fingerprints in
neuroimaging. If Psychiatry is to take:
“an honest reflection on trends and approaches the
field has taken to date, and reckoning with their
assumptions and impact”
as Etkin (148) asked of the field, we may come to agree with
him that we are at “an important inflection point for the field.”
That inflection point is the acceptance of functional
neuroimaging as a diagnostic tool, not to stand alone, but to
aid, direct, and guide the ordering diagnostician to a better and
more efficient evaluation and treatment of the neurobiological
processes that underlie a particular patient's symptoms.
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